// App-Quantinova.ai

1008 : Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).

Researchers

Presenter

  • Amit Bahl

Principal Investigators

  • Alicia Bravo

  • Emily Foulstone

  • Jessica Ball

  • Mark Churn

  • Sidharth Dubey

  • Saiqa Spensley

  • Rebecca Bowen

  • Simon Waters

  • Pippa Riddle

  • Duncan Wheatley

  • Peter Stephens

  • Janine Mansi

  • Pavel Bezecny

  • Srinivasan Madhusudan

  • Mark Verrill

  • Alison Markham

  • Sylvia Pearson

  • William Wilson

Medical Centers

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Worcester Royal Hospital, Worcester, United Kingdom

  • Derriford Hospital, Plymouth, United Kingdom

  • Musgrove Hospital, Taunton, United Kingdom

  • Royal United Hospital NHS Foundation Trust, Bath, United Kingdom,

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • Charing Cross Hospital, London, United Kingdom

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust and Kings College Medical School, London, United Kingdom

  • Blackpool Teaching Hospitals, Blackpool, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Cancer Research UK and UCL Cancer Trials Centre, University College London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Granulocyte colony-stimulating factor

  • Human epidermal growth factor receptor 2

  • Transthyretin

Drug/Treatment

  • Cabazitaxel

  • Paclitaxel

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03048942

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved